Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McNeil Motrin Migraine Pain, Aflexa Supplement National Ads Breaking Soon

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer Healthcare's Motrin Migraine Pain is reaching food, drug and mass store shelves now; the product began shipping nationwide April 5.

You may also be interested in...



Perrigo Indication-Specific Analgesics Slated For Mid-2001 Launch

Perrigo plans to launch a Women's Menstrual Relief analgesic in April, comparable to McNeil Consumer Healthcare's Women's Tylenol, which debuted in October.

Perrigo Indication-Specific Analgesics Slated For Mid-2001 Launch

Perrigo plans to launch a Women's Menstrual Relief analgesic in April, comparable to McNeil Consumer Healthcare's Women's Tylenol, which debuted in October.

Perrigo Indication-Specific Analgesics Slated For Mid-2001 Launch

Perrigo plans to launch a Women's Menstrual Relief analgesic in April, comparable to McNeil Consumer Healthcare's Women's Tylenol, which debuted in October.

Related Content

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel